Objective  To investigate predictive effect of serum beta human chorionic gonadotropin(β-HCG) on unruptured tubal pregnancy treated by methotrexate(MTX).

  Methods  A total of 197 patients with unruptured tubal pregnancy treated with MTX were selected and divided into success group (n=138) and failure group (n=59) according to the results of MTX treatment. The changes of blood β-HCG levels in the two groups were compared, and the sensitivity and specificity of blood β-HCG in predicting therapeutic efficacy of MTX were analyzed by Receiver Operating Characteristic (ROC) curve.

  Results  In the successful group, ratio of patients with the level of β-HCG decreased by 91.30%(126/138)on the fourth day was significantly higher than 20.34%(12/59) in those of the failure group(P < 0.05). The change rate of β-HCG ranging from the first day to the fourth day and β-HCG levels at 4 and 7 days after administration of two groups showed significant differences(P < 0.05). ROC curve analysis results showed that the β-HCG level on the 1st day was the highest in specificity, and was the highest on the 4th day in sensitivity. Comprehensive analysis showed that β-HCG level on the 4th day had a higher predictive value for MTX treatment outcomes. Out of 197 patients, 11 had nausea and vomiting, and 5 had slight increase of transaminase level.

  Conclusion  For asymptomatic and stable ectopic pregnancy women in hemodynamics, it is a safe and effective and choice to predict the effect of MTX in the treatment of unruptured tubal pregnancy through the changes of serum β-HCG.